Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Chemoprevention in Barrett's Esophagus
NCT01447927Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in Barrett's esophagus and esophageal cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus at 3 months. Started Jun 2012; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Barrett's esophagusesophageal cancer
Beyond the preview
Go deeper on NCT01447927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01447927.